Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction - Comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study) -

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 908-916

  Nagai, Ryozo ^a   Kinugawa, Koichiro ^b   Inoue, Hiroshi ^c   Atarashi, Hirotsugu ^d   Seino, Yoshihiko ^e   Yamashita, Takeshi ^f   Shimizu, Wataru ^g   Aiba, Takeshi ^g   Kitakaze, Masafumi ^g   Sakamoto, Atsuhiro ^h   Ikeda, Takanori ⁱ   Imai, Yasushi ^b   Daimon, Takashi ^j   Fujino, Katsuhiro ^k   Nagano, Tetsuji ^k   Okamura, Tatsuaki ^k   Hori, Masatsugu ^l  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^e NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^f THE CARDIOVASCULAR INSTITUTE   (Japan)

^g NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^h NIPPON MEDICAL SCHOOL   (Japan)

ⁱ TOHO UNIVERSITY   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

^k ONO PHARMACEUTICAL CO   (Japan)

^l OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

more..

Author keywords

blocker; Atrial fibrillation; Atrial flutter; Landiolol; Left ventricular dysfunction

Indexed keywords

DIGITALIS; DIGOXIN; LANDIOLOL;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES INSIPIDUS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUS ARREST; TACHYCARDIA; UREA BLOOD LEVEL; VOMITING;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FLUTTER; DIGOXIN; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; TACHYCARDIA; UREA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84875498187     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1618     Document Type: Article

References (24)

1. Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, et al; JCARE-CARD Investigators. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 2084-2090.
2. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D.
3. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute decompensated heart failure syndromes (ATTEND) registry: A prospective observational multicenter cohort study: Rationale, design, and preliminary data. Am Heart J 2010; 159: 949-955.
4. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010; 74: 2479-2500.
5. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30: 1039-1045.
6. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
7. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Am J Med 1988; 85: 242-244.
8. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1570-1573.
9. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198.
10. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation: Results of a randomized, placebo-controlled multicentre trial in 239 patients: The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997; 18: 649-654.
11. Shiroya T, Ichioka Y, Yoshida K, Nishijima K, Omawari N, Naka M, et al. Pharmacological studies of ONO-1101 as a beta-blocking agent with high beta 1 selectivity and ultra-short duration of action. Kiso To Rinsho 1997; 31: 2913-2923 (in Japanese).
12. Sakamoto A, Kitakaze M, Takamoto S, Namiki A, Kasanuki H, Hosoda S; JL-KNIGHT study group. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: Prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J 2012; 76: 1097-1101.
13. Hanada K, Higuma T, Nishizaki F, Sukekawa T, Yokota T, Yamada M, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2012; 76: 439-445.
14. Kobayashi S, Susa T, Tanaka T, Murakami W, Fukuta S, Okuda S, et al. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J 2012; 76: 1646-1653.
15. Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshida K, Yanagisawa R, et al. Effects of landiolol, an ultra-short-acting β1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J 2010; 74: 856-863.
16. Pinter A, Dorian P, Paquette M, Ng A, Burns M, Spanu I, et al. Left ventricular performance during acute rate control in atrial fibrillation: The importance of heart rate and agent used. J Cardiovasc Pharmacol Ther 2003; 8: 17-24.
17. Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604-618.
18. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009; 37: 2174-2179.
19. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373.
20. Gray RJ, Bateman TM, Czer LS, Conklin CM, Matloff JM. Esmolol: A new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol 1985; 5: 1451-1456.
21. Dias VC, Weir SJ, Ellenbogen KA. Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. Circulation 1992; 86: 1421-1428.
22. Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, Roden DM, et al. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 2012; 59: 49-56.
23. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
24. Hofmann R, Steinwender C, Kammler J, Kypta A, Wimmer G, Leisch F. Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr 2004; 116: 744-749.